Clinical Trial Update: Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study [Phase 3]

View source ↗

Summary

A Phase 3 pilot open-label study of imiquimod 5% cream for plaque-type morphea was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Localized Scleroderma

Drugs mentioned

• Imiquimod 5% cream (Imiquimod)

Snippet

Sponsor: University of Alberta | Conditions: Morphea | Phase 3 | Status: WITHDRAWN